Search

Your search keyword '"Chen, Edmond"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Chen, Edmond" Remove constraint Author: "Chen, Edmond"
41 results on '"Chen, Edmond"'

Search Results

2. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

3. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial

4. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial)

5. Usefulness and Safety of Vorapaxar in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial)

6. Association of Aspirin Dose and Vorapaxar Safety and Efficacy in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome (from the TRACER Trial)

7. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

8. Electrifying Change : An Analysis of Streetlight Electric Vehicle Charging Around Multi-Family Residential Units in Vancouver

9. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: Insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)

10. Supplement to: Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

11. Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial

12. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial

13. Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes

14. Contributors

16. Inaccurate electrocardiographic interpretation of long QT: The majority of physicians cannot recognize a long QT when they see one

17. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

18. Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial

19. Effect of age on efficacy and safety of vorapaxar in patients with non–ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial

20. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar

21. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial

22. Vorapaxar in Acute Coronary Syndrome Patients Undergoing Coronary Artery Bypass Graft Surgery

23. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes

24. EFFECTS OF GLYCOPROTEIN IIB/IIIA INHIBITORS IN COMBINATION WITH VORAPAXAR, A PLATELET THROMBIN-RECEPTOR ANTAGONIST, AMONG PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE TRACER TRIAL

26. Abstract 9964: Vorapaxar, a Platelet Thrombin-Receptor Antagonist, in Medically Managed Patients with Non-ST-Segment Elevation Acute Coronary Syndrome: Results from the TRACER Trial

27. Abstract 18805: Vorapaxar, A Platelet Thrombin-Receptor Antagonist, in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Results from the TRACER Trial

30. REDUCTION OF MYOCARDIAL INFARCTION WITH VORAPAXAR: RESULTS FROM THE TRA·CER TRIAL

33. PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL

34. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies(COMPASS) Trial

36. Relation Between Hospital Intra-Aortic Balloon Counterpulsation Volume and Mortality in Acute Myocardial Infarction Complicated by Cardiogenic Shock

37. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes

41. Contributors

Catalog

Books, media, physical & digital resources